Grunenthal GmbH et al. vs Antecip Bioventures II LLC

Patent Owner's Notice of Appeal

Rehearing Decision Denying Patent Owner's Request for Rehearing

Petitioner's Response to Patent Owner's Request for Rehearing

ORDER - Authorizing Petitioner¿¿¿s Response To Patent Owner¿¿¿s Request for Rehearing 37 C.F.R. 42.5

Patent Owner Request for Rehearing

Termination Decision Document

Hearing Transcript

Patent Owner's Opposition to Petitioner's Motion to Exclude

Petitioner's Opposition to Patent Owner's Motion to Exclude Evidence

ORDER - Oral Hearing 37 C.F.R. ¿¿ 42.70

Patent Owner's Motion to Exclude

Patent Owner's Request for Oral Argument

Petitioner's Motion to Exclude Evidence

Petitioner's Request for Oral Argument

Patent Owner's Surreply

Patent Owner's Objections to Petitioner's Reply Evidence

Deposition Transcript Dr. William Wargin (PGR2017-00022)

Deposition Transcript of Dr. William Wargin (Oct. 25, 2018)

Affidavit of Christopher Butler

Petitioner's Third Amended Exhibit List

Petitioner's Second Updated Mandatory Notices

Petitioner's Reply

Information Disclosure Statement from U.S. Pat. App. No. 13/894,244

Order - Granting Patent Owner's Request for Authorization to File a Sur-Reply - 37 CFR 42.5(a), 42.24(c)(1)

Notice of Stipulation Regarding Schedule

Petitioner's Notice of Deposition of Dr. William Wargin

ORDER Denying Petitioner's Motion to Compel Routine Discovery And Denying Petitioner's Motion for Additional Discovery 37 C.F.R. §§ 42.51, 42.65, 42.224

Patent Owner's Opposition to Petitioner's Motion to Compel Routine Discovery and, in the Alternative, for Additional Discovery

FDA Guidance for Clinical Trial Sponsors

Petitioner's Second Amended Exhibit List

Petitioner's Motion to Compel Routine Discovery and, in the Alternative, for Additional Discovery

Axsome Therapeutics, Inc. Press Release

ORDER Granting Petitioner's Request for Authorization to File a Motion to Compel Routine Discovery and, In the Alternative, for Additional Discovery

Petitioner's Objections to Evidence

Declaration of Brent A. Johnson

Wargin CV

Declaration of Stephen Bruehl

Patent Owner Response

Declaration of Quincy J. Chuck

Didronel

Skelid Label

Degrossi et al.

US Patent App. No. 20130035315A1

Deposition Transcript of Wilson

Brown et al.

Declaration of Dr. William Wargin

US Patent App. No. 20130303485 A1

Reply Declaration of Dr. Clive G. Wilson

Deposition Transcript of Stephen Bruehl

Reclast Label

Screenshot of Google search for "fda ivivc guideline"

DiMasi et al.

AXS-02 Phase 1 Results Summary

Hummel et al.

Patent Owner's Second Updated Exhibit List

Patent Owner's Notice of Deposition of Clive G. Wilson

Petitioner's Objections to Evidence

Patent Owner's Objections to Petitioner's Petition Evidence

Trial Instituted Document

Scheduling Order

Patent Owners Motion for Pro Hac Vice Admission of Michael Katz 37 C.F.R. sec 42.10(c)

Petitioners Motion for Pro Hac Vice Admission of James R. Tyminski Jr. and Ms. Melinda R. Roberts 37 C.F.R. sec 42.10(c)

Exhibit 2008

Notice of Patent Owner's Disclaimer of Patent Claim Under 37 CFR 1.321

Patent Owner's Updated Exhibit List

Petitioner's Updated Mandatory Notices

Transcript of Deposition of Clive G. Wilson

Patent Owner's Preliminary Response

Conte

U.S. Patent No. 9,283,239

US Patent Application No. 20110028435

Expert Declaration of Stephen Bruehl

Patent Owner's Exhibit List

Transcript of Deposition of Stephen Bruehl, Ph.D.

Patent Owner's Motion for Pro Hac Vice Admission of Michael Katz

Declaration of Michael Katz in Support of Patent Owner's Motion for Pro Hac Vice Admission

Petitioner's First Amended Exhibit List

Petitioner's Motion for Pro Hac Vice Admission of James R. Tyminski Jr. Under 37 C.F.R. 42.10

Declaration in Support of Petitioner's Motion for Pro Hac Vice Admission of James R. Tyminski Jr.

Petitioner's Motion for Pro Hac Vice Admission of Melinda R. Roberts Under 37 C.F.R. 42.10

Declaration in Support of Petitioner's Motion for Pro Hac Vice Admission of Melinda R. Roberts

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

Power of Attorney

File History of U.S. Patent No. 9,539,268

Declaration of Stephen Bruehl, Ph.D.

U.S. Patent No. 9,539,268

Curriculum vitae of Clive G. Wilson, Ph.D.

Fox

Laslett

Leonard

De Castro

Fosamax Drug Label

Zometa Drug Label

Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms

What is this thing called pain?

Int'l Patent App. Pub. No. WO2011/014781

Declaration of Clive G. Wilson, Ph.D.

MER-101 tablets: A pilot bioavailability study of a novel oral formulation of zoledronic acid

Annex 2: WHO good mfg practices for pharm. prods.: main principles

Absorption Enhancers: Applications and Advances

The osteoarthritis knee model: psychophysical characteristics and putative outcomes

Bisphosphonates: Potential therapeutic agents for disease modification in osteoarthritis

The Relationship of Antiresorptive Drug Use to Structural Findings and Symptoms of Knee Osteoarthritis

Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance

Painful prosthesis: approaching the patient with persistent pain following total hip and knee arthroplasty

Prospective examination of pain-related and psychological predictors of CRPS-like phenomena following total knee arthroplasty: a preliminary study

Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management

Eliminating the need for fasting with oral administration of bisphosphonates

Zoledronate disodium: Treatment of tumor-induced hypercalcemia angiogenesis inhibitor

Aronhime

Excerpts from File History of U.S. Patent No. 7,704,977

Merrion Poster

U.S. Patent No. 9,216,168

Curriculum vitae of Stephen Bruehl, Ph.D.

Lifetime Risk and Age at Diagnosis of Symptomatic Knee Osteoarthritis in the U.S.

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial

Nociception, pain, and antinociception: current concepts

Osteoarthritis: toward a comprehensive understanding of pathological mechanism

Associations between KCNJ6 (GIRK2) gene polymorphisms and pain-related phenotypes

Handbook of Pharm. Excipients Excerpts

Chapter 3: Pharmacokinetics in Modern Pharm.

Studies of bioavailability and food effects of MER-101 zoledronic acid tablets in postmenopausal women Poster Presentation

U.S. Patent App. No. 13/394,244 Pages 1-300

Development of a severity score for CRPS

Studies of bioavailability and food effects of of MER-101 zoledronic acid tablets in postmenopausal women

U.S. Patent App. No. 13/394,244 Pages 301-600

U.S. Patent App. No. 13/394,244 Pages 601-900

U.S. Patent App. No. 13/394,244 Pages 1201-1500

U.S. Patent App. No. 13/394,244 Pages 1501-1800

A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients

Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis Study

Imaging Studies in Freund's Complete Adjuvant Model of Regional Polyarthritis, a Model Suitable for the Study of Pain Mechanisms, in the Rat

Characterisation of a Freund's complete adjuvant-induced model of chronic arthritis in mice

Chapter 59: Clin. Pharmacokinetics in Remington's Pharm. Sci.

Comparison of Gastrointestinal pH in Dogs and Humans: Implications on the Use of the Beagle Dog as a Model for Oral Absorption in Humans

U.S. Patent App. No. 13/394,244 Pages 901-1200

U.S. Patent App. No. 13/394,244 Pages 1801-1982

U.S. Patent App. Pub. No. 2014/0051669

U.S. Patent No. 9,408,862

File History of U.S. Patent No. 9,408,862

Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis

The effect of alendronate on progression of spinal osteophytes and disc-space narrowing

Chapter 38: Preformulation in Remington's Pharm. Sci.

Chapter 53: Bioavailability & Bioequivalence Testing in Remington's Pharm. Sci.

Gastric pH Profile and Its Control in Fasting Beagle Dogs

Petition for Post Grant Review of U.S. Patent No. 9,539,268